📊 Score Breakdown
Offering Ability
90
Cash Runway
40
Float Risk
25
Warrant Exposure
15
Convertible Debt—
🌦️ Dilution Forecast
🌥️
Advisory
Moderate dilution signals present
36%
🔁 Convertible Conversion
40%
• Significant convertible debt: 24% potential dilution
• Elevated convertible risk (60/100)
📉 Score Deterioration
40%
• Score rose 38 points recently (worsening)
💰 Capital Raise
20%
• Active shelf registration ($20M, 399% of market cap)
💹 Market Data
Market Cap$4.88M
Shares Outstanding950.3K
Float835.4K
Cash$17.81M
DebtN/A
Short InterestN/A
🏛 Institutional Holdings
QoQ: ↓ 73.1% shares (2025Q4 vs prior)
6 institutional holders · 3.9K shares
#1
UBS Group AG
3.0K shares
#2
Tower Research Capital LLC (TRC)
887 shares
#3
BANK OF AMERICA CORP /DE/
16 shares
+ 3 more holders Sign up free to view →
📉 Short Interest
Short Interest36.3K
Days to Cover4.1
% of Float4.3%
FINRA data as of May 15, 2026
📁 Recent SEC Activity
xbrl
XBRL WARRANT
Dec 31, 2025
xbrl
XBRL CONVERTIBLE
Dec 31, 2021
S-1
SHELF
May 01, 2026
S-3
SHELF
Apr 30, 2026
8-K
8K EVENT
Apr 07, 2026
Full SEC filing analysis available with free account →
📰 Recent News
No recent news
🔬 More Research for RNAZ
📊 RNAZ FDA Catalyst Timeline & Biotech Grade — BiotechSigns
📡 RNAZ Signal Convergence & Dark Pool Activity — StonkWhisper
Part of the Guerilla Finance research network. Cross-reference multiple data sources for better due diligence.